Sam is a professional trader and the lead stock market news writer at AskTraders. After starting his career in the forex market, Sam now focuses on gold and stocks with a preference for fundamental and macroeconomic analysis.
Biotechnology firm, AIkido Pharma's (NASDAQ: AIKI) share price has plunged on Wednesday after the company announced it has entered into an underwriting agreement with H.C. Wainwright & Co under which the underwriter has agreed to purchase 6.25 million shares for $1.60 per share.
The company has granted H.C. Wainwright a 30-day option to purchase up to an additional 937,500 shares of common stock at the public offering price. The closing of the offering is expected to occur on or around the 19th of February.
The Virginia based company said it intends to use the proceeds for working capital and general corporate purposes.
AIkido’s share price is down 22.77% so far on Wednesday, trading at $1.65 after reaching highs of $2.55 during Tuesday's session. For the year to date, its stock has gained over 84%.
CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage . 75 % of retail investor accounts lose money when trading CFDs with this provider . You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money .